Title:
IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-β OLIGOMERS
Document Type and Number:
WIPO Patent Application WO/2024/032822
Kind Code:
A1
Abstract:
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of a W20 antibody. Compared with the W20 antibody, the improved form of the W20 antibody has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the W20 antibody. The improved form of the antibody can specifically bind to a highly toxic amyloid oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the W20 antibody is as shown in SEQ ID NO: 1.
Inventors:
LIU RUITIAN (CN)
YU XIAOLIN (CN)
LU SHUAI (CN)
YANG JINJU (CN)
ZHU JIE (CN)
YU XIAOLIN (CN)
LU SHUAI (CN)
YANG JINJU (CN)
ZHU JIE (CN)
Application Number:
PCT/CN2023/121350
Publication Date:
February 15, 2024
Filing Date:
September 26, 2023
Export Citation:
Assignee:
SHEN ZHEN WISDOM BIOPHARM CO LTD (CN)
International Classes:
C07K16/18; A61K39/395; A61P25/28; C12N1/21; G01N33/577
Domestic Patent References:
| WO2011130377A2 | 2011-10-20 | |||
| WO2013167681A1 | 2013-11-14 |
Foreign References:
| CN101463082A | 2009-06-24 | |||
| CN102597234A | 2012-07-18 | |||
| CN103179981A | 2013-06-26 | |||
| US20100202968A1 | 2010-08-12 |
Attorney, Agent or Firm:
BEIJING INTELLEGAL INTELLECTUAL PROPERTY AGENT LTD. (CN)
Download PDF:
Previous Patent: HIGHLY TOXIC AMYLOID OLIGOMER AND USE THEREOF
Next Patent: DIAGNOSTIC USE OF HIGHLY TOXIC AMYLOID OLIGOMER
Next Patent: DIAGNOSTIC USE OF HIGHLY TOXIC AMYLOID OLIGOMER